Capecitabine in ER+/HER2-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

ER-positive, HER2-negative Breast Cancer · Breast Cancer Stage I · Breast Cancer Stage II · Breast Cancer Stage III

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UHN - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (David Cescon) · Dave.Cescon@uhn.ca · 416-946-2245
Contact: Principal Investigator (Dave Cescon)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Irvine, United States

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Irvine, United States · La Jolla, United States

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Breast Cancer · Cancer of the Breast

Abroad (travel likely)RecruitingPHASE2

St Louis, United States

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Sankt Gallen, Switzerland · Genolier, Switzerland